|
Synonyms: BMS-901608 | Empliciti® | HuLuc63
elotuzumab is an approved drug (FDA (2015), EMA (2016))
Compound class:
Antibody
Comment: Elotuzumab is a humanized IgG1 antibody targeting CS1 (SLAMF7) [1-2].
Peptide sequences for elotuzumab are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Elotuzumab targets the CS1 surface glycoprotein that is highly expressed in primary tumor cells from the majority of MM patients [2]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
CS1 expression is elevated in patients with SLE suggesting that CS1-targeted inhibition may be effective in this condition. | |
| Multiple myeloma |
Disease Ontology:
DOID:9538 OMIM: 254500 |
Approved drug for MM. | |
